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Dear Sir,
We read with interest the recently published letter by
Zanotti-Fregonara et al. [1] that very critically discusses the
characteristics of 18F-GE180 as a PET tracer for the 18-kDa
mitochondrial translocator protein (TSPO) in human brain.
This follows a previously published and rather similar letter
and thus offers little information that is substantially new [2].
The main hypotheses of Zanotti-Fregonara et al. [1] are still
that
1. The uptake of 18F-GE180 is not specific for TSPO and
insteadmainly reflects a broken and disrupted blood-brain
barrier (BBB)
2. The sensitivity of the tracer must be low because differ-
ences in tracer binding cannot be detected between bind-
ing affinity types in vivo
The evidence that Zanotti-Fregonara et al. present in sup-
port of these hypotheses is not valid. From our point of view,
the complete discreditation of a tracer is a harsh assessment
and one that must be firmly based on scientifically conclusive
evidence. Taking into consideration all published data as well
as our own experience with the tracer, the arguments of the
authors, although partially understandable, are not sufficient
to support their general dismissal of 18F-GE180.
In our studies of glioma patients [3–5], we found that 18F-
GE180 PET tracer uptake could be clearly visualized on the
PET image in areas outside of the gadolinium enhancement
area on MRI and even in gliomas without any visible contrast
enhancement on MRI; Zanotti-Fregonara et al. argue that the
BBB in these areas might be disrupted in terms of a
microdisruption which is simply not depicted on MRI. We
fully agree that the presence of an “MRI-invisible
microdisruption” of the BBB in these cases cannot be ruled
out. However, even if there was a microdisruption of the BBB,
which can only be passed by the PET imaging probe and not
by gadolinium, the hypothesis that the accumulation of 18F-
GE180 beyond the BBB is merely nonspecific signal and is a
speculation that is not firmly based on scientifically conclu-
sive evidence. We claim that TSPO-expressing tissue beyond
the BBB is required for the highly increased tracer signal
found in our glioma studies. Our conclusion is based on sev-
eral findings:
1. If a tracer signal reflects BBB breakdown only, one would
expect to find an increased signal in all areas with
disrupted BBB. In this context, Zanotti-Fregonara correct-
ly stated that “the direction of the mismatch is important”
and “If the gadolinium area is larger than that of 18F-
GE180, one can plausibly argue for a dissociation be-
tween 18F-GE180 uptake and BBB breakdown.” [1]. In
our earlier response letter [6], we presented an example of
a patient with clear BBB breakdown (ring enhancing gli-
oma lesion after radiotherapy), but without significant
18F-GE180 uptake in this area (see Fig. 1). This finding
together with the intense tracer accumulation found in
many other lesions without visible contrast enhancement
in MRI makes it very unlikely that the cerebral uptake of
18F-GE180 is driven by the BBB disruption only. The
authors appear to have disregarded this argument in their
current letter [1]. The discrepancy between gadolinium
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enhancement and tracer signal in the presented
direction—as suggested by Zanott i-Fregonara
et al.—clearly points to a specific component necessary
for sustained 18F-GE180 binding.
2. If the 18F-GE180 signal is primarily reflective of nonspe-
cific tracer accumulation predominantly driven by disrup-
tion of the BBB, one would expect a correlation between
the level of BBB disruption and 18F-GE180 signal inten-
sity. However, there is in our experience no correlation
between BBB disruption as assessed using contrast-
enhanced MRI and the 18F-GE180 signal intensity (see
Fig. 2 for an example).
3. Another argument for the specific binding of 18F-GE180
to TSPO is given by very similar binding patterns when
comparing in vitro autoradiography with ex vivo autora-
diography in animal models (Fig. 3).
Zanotti-Fregonara et al. insist on the importance of a cor-
relation of in vivo 18F-GE180 uptake with histopathological
analysis using stereotactic brain biopsies.We have an ongoing
publicly funded study correlating 18F-GE180 uptake and his-
topathology in brain tumours exactly addressing this issue
(German Research Foundation, FOR 2858; project A1 and
A2). We evaluate here in-depth the correlation between
TSPO expression and 18F-GE180 uptake in humans and hope
to reproduce the promising results obtained in preclinical stud-
ies; e.g., Parhizkar et al. were able to demonstrate a strong
correlation between the phagocytosis marker CD68 and the
18F-GE180μPET signal in a transgenic amyloid mouse model
[7]. Significant associations between 18F-GE180 PET and mi-
croglia immunohistochemistry were also proven for the more
general microglia activation marker Iba1 in different amyloid
mouse models [8, 9]. Considering this variety of evidence
together with the minor impact of BBB leakage in amyloid
mouse models, it seems very unlikely that a parallel BBB-
related phenomenon confounds all observed associations of
PET with gold standard assessments.
Zanotti-Fregonara et al. are of course correct in stating that
the disruption of the BBB has an influence on the 18F-GE180
uptake, but this is a phenomenon that is more or less shared
among all other TSPO tracers. To our knowledge, no publi-
cation has proven that the uptake of any other TSPO tracers
e.g. is not influenced by the BBB disruption. Zanotti-
Fregonara et al. themselves provide an example for the
TSPO tracer 11C-ER176, which shows moderate uptake with-
in the area of increased 82Rb-PET signal and contrast enhance-
ment on MRI, but not beyond [1]. This tracer together with
several other TSPO tracers has, compared with 18F-GE180,
the disadvantage of exhibiting a very high fraction of
metabolised tracer potentially contributing to tracer signal in
regions with disrupted BBB. In contrast, 18F-GE180 has a
favourably high parent fraction even at late time points [10,
11].
Furthermore, the statement by Zanotti-Fregonara et al. at-
tributing the reported positive correlation of 18F-GE180 signal
and the WHO grade in glioma [3] to increased levels of BBB
disruption only is not correct. It may be true that the level of
BBB disruption is—in many cases—higher in high-grade
than in low-grade gliomas; however, up to 40% of gliomas
Fig. 1 Example of a patient with
a glioblastoma multiforme after
radiotherapy: on MRI, there is a
remaining contrast enhancement
reflecting major BBB disruption;
in the 18F-GE180 PET, no
relevant corresponding tracer
uptake can be found, showing that
a mere macro-disruption of the
BBB does not necessarily lead to
a highly elevated, nonspecific
tracer accumulation (PET image
is SUV scaled)
2238 Eur J Nucl Med Mol Imaging (2020) 47:2237–2241
without contrast enhancement onMRI are high-grade gliomas
[12, 13]. TSPO expression itself is, independent of potential
BBB disruption, also highly correlated with the WHO grade
as shown by neuropathological studies [14]. Nonetheless, we
agree with Zanotti-Fregonara et al. that the data on normal
volunteers indicate that a certain basic microdisruption might
be necessary for 18F-GE180 accumulation and therefore,
TSPO-expression in an area completely without BBB-
disruption might be underestimated by 18F-GE180 PET.
However, as mentioned above, there is barely any clinical
situation, in which brain pathologies (e.g. neuroinflammatory
processes, gliomas, or their local co-existence) are not accom-
panied by at least a minor disruption of the BBB. Thus, this
phenomenon cannot be ruled and is not of major practical
Fig. 2 Example of a patient with a newly diagnosed glioblastoma—
already the visual inspection shows that the maximal tracer signal can
be found in the areas surrounding the contrast-enhancing ring lesion; the
voxel-wise correlation of 18F-GE180 (tumour-to-background ratio
(TBR); background assessed in 6 crescent-shaped regions-of-interest in
the contralateral hemisphere according to [19]) and gadolinium signal
intensity (TBR) [22] within all suspicious voxels on T2w MRI clearly
reveals no significant association. To be more specific, the big cluster
with contrast enhancement on background level (TBR ~ 1) shows in-
creased uptake with a wide range of voxel values on 18F-GE180 PET.
Moreover, even for voxels with contrast enhancement on MRI, no corre-
lation with 18F-GE180 uptake can be identified
Fig. 3 Example of a mouse
glioblastoma with high tracer
binding in the ex vivo
autoradiography (left) performed
following a 18F-GE180 PET scan
and same signal pattern in the
in vitro autoradiography (right).
For the in vitro autoradiography,
the tracer 18F-GE180 is applied
directly to the slices (here even to
the corresponding slice for opti-
mal comparability) several days
and weeks later. The tracer signal
here is clearly not related to a
blood-brain-barrier disruption
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relevance in investigating the diseased brain. It is of course
highly desirable to understand in-depth the influence of BBB
breakdown on 18F-GE180 uptake and similar tracers, e. g. by
using adequate methodology including multi-modal PET and
elaborate MRI analyses.
In their most recent letter, Zanotti-Fregonara et al. state:
“The substantial role of BBB disruption in the uptake of 18F-
GE180 is clearly shown in a recent pilot study in patients with
ischemic lesions […]. The authors found that a significant part
of the high uptake in the lesions is nonspecific and driven by
BBB damage. Furthermore, up to 50% of the signal in
nonischemic brain is due to vascular noise.” [1]. Keeping in
mind that the signal fraction caused by vasculature has been
reported to be about 20% for 18F-GE180 [11] (and not 50%)
of the signal in healthy tissue at late time points (best
representing distribution volumes), we do not support the
above-drawn conclusions of Zanotti-Fregonara et al. A high
vascular proportion of tissue signal of up to 50% is only true
for the very early time frames (15–30 min post injection) used
by Visi et al., which do not represent distribution volume [11].
Their hypothesis that high 18F-GE180 uptake in lesions is
mainly non-specific is only based on the observation that a
high uptake in one low-affinity binder (LAB) lesion was
found in early static images, see [15]. Visi et al. observed
otherwise a high correlation of lesion-to-reference ratios of
the early 18F-GE180 signal with distribution volume ratios
obtained using 11C-(R)-PK11195, indicating very similar
in vivo behaviour [15]. This included the uptake in both ob-
served LAB lesions. Due to the unclear susceptibility to TSPO
polymorphism in vivo [10, 11, 16, 17], we believe that the
high uptake in one LAB lesion does not prove non-specificity
of the 18F-GE180 signal, but rather likely represents disease
severity and TSPO expression level similar to 11C-(R)-
PK11195.
With respect to the authors’ second claim that “the quality
of the images is so poor that even a difference this large cannot
be consistently detected” [1], we primarily refer to our previ-
ous reply letter [6]. The controversial results reported for 18F-
GE180 uptake in healthy volunteers with different binding
affinity status could be attributed to the low target expression
in healthy tissue itself and the technical difficulties associated
with 18F-GE180 quantification, see e. g. [17]. Moreover, one
has to discuss to what extent the diagnostic quality of a tracer
is limited by a very low signal of the tracer in healthy brain. A
high target-to-background ratio allowing sensitive detection
of TSPO expressing diseased tissue is the primary goal in a
clinical setting. We believe that 18F-GE180 has suitable char-
acteristics for that. It is quite obvious that specific tracer up-
take is (besides the extensively discussed influence of BBB
disruption) heavily influenced by the pathology itself, in such
a way that potential differences induced by the binding affin-
ity status in pathological lesions are very hard to detect; e.g., in
patients with brain tumours, tumoural aggressiveness and
inflammatory activity have amajor effect on TSPO expression
and will mask differences between the diverging binding af-
finity status at least for high- and medium-affinity binders,
which represent the majority of the patients.
In summary, we reject the claim of Zanotti-Fregonara et al.
that 18F-GE180 is a “failed radioligand”. Vice versa, we
would like to clarify that 18F-GE180 cannot legitimately be
called “superior” or an ideal radioligand in the light of the
given limitations highlighted in the joint discussion [1, 2, 6].
We believe that a “perfect” radioligand targeting the TSPO
does not (yet) exist—neither 18F-GE180 nor any other ligand
so far—as every existing TSPO radioligand suffers drawbacks
[18], which have to be weighed and thoughtfully considered
during data interpretation. However, for beneficial routine
clinical use, one has to compromise when dealing with the
limitations of TSPO ligands. We believe—despite the
discussed drawbacks of 18F-GE180—that imaging with 18F-
GE180 can add comprehensive clinical information: First, we
think that 18F-GE180-uptake in patients with multiple sclero-
sis and clinical worsening despite unchanged and non-
enhancing lesions on MRI can indicate remaining disease ac-
tivity [19, 20]—independent of the very exact contribution of
the BBB on 18F-GE180 uptake. In these patients, standard
imaging with contrast-enhanced MRI is less sensitive in
assessing the change of the clinical situation. Second—also
independent of the very exact contribution of the BBB on 18F-
GE180 uptake—we believe that imaging with 18F-GE180 can
significantly add clinical information in brain tumour patients
by delineating the tumour extent beyond contrast enhance-
ment on MRI [3–5, 21] and, in future, probably by depicting
in more detail, compared with labelled amino acids, the tu-
mour characteristics. Therefore, in summary, we believe that
despite the repeated articulation of 18F-GE180 PET draw-
backs, its use can significantly contribute to clinical issues that
thus far cannot be resolved with standard imaging alone.
Finally, we wanted to strongly emphasize our appreciation
of Dr. Owen’s previous and current work. We do not doubt
Dr. Owen’s theses in personal communications at all, as prob-
ably inadvertently indicated by Zanotti-Fregonara et al. [1].
By contrast, we rather wanted to encourage the authors to
further obtain and publish data on in vitro affinity to TSPO
polymorphism in order to foster fruitful exchange and help to
solve the common controversial and important issues.
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